Close Menu
NEW YORK (GenomeWeb News) – Luminex today announced that it has licensed its xMAP technology and the Luminex Bioscience Group’s assay development capabilities to Wageningen University and Research Center in the Netherlands.
 
Wageningen will use the xMAP multiplex technology for a variety of agricultural biotech areas including plant pathogen detection, epidemiology, food safety, and marker-assisted plant and animal breeding programs. Financial terms of the agreement were not disclosed.
 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The FDA and CDC call for a pause in administering Johnson & Johnson's SARS-CoV-2 vaccine while reports of rare blood clots are looked into, reports the Wall Street Journal.

According to the Associated Press, a Swiss program aims to shepherd long-term science projects and diplomacy.

CNN reports that two new studies suggest the B.1.1.7 SARS-CoV-2 variant may be more transmissible, but may not lead to more severe disease.

In PNAS this week: analysis of pathway affecting acute kidney injury, parental-specific allelic expression in horse placenta, and more.